

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/99. CMB 0051-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/127370
		Filing Date	
		First Named Inventor	DAVID YOUNG
		Group An Unit	
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	2056.008

JCE86 U.S. PTO
09/127370
11/29/00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T
LB		Badger CC, Bernstein ID. Prospects for monoclonal antibody therapy of leukemia and lymphoma. Cancer. Vol. 58. 1986. pp. 584-9.	
LB		Begg AC, Mooren E. Rapid fluorescence-based assay for radiosensitivity and chemosensitivity testing in mammalian cells in vitro. Cancer Research. Vol. 49. 1989. pp. 565-9.	X
LBH		Boven E, Pinedo HM. Monoclonal antibodies in cancer treatment: where do we stand after 10 years? Radiotherapy & Oncology, Vol. 5. 1986. pp. 109-17.	
LPA		Costa A, Silvestrini R, Del Bino G, Motta R. Implications of disaggregation procedures on biological representation of human solid tumours. Cell Tissue Kinet. Vol. 20. 1987. pp. 171-80.	>
LB		Dairkee SH, Paulo EC, Traquina P, Moore DH, Ljung BM, Smith HS. Partial enzymatic degradation of stroma allows enrichment and expansion of primary breast tumor cells. Cancer Res. Vol. 57. 1997. pp. 1590-6.	>
LB		Dillman RO. Monoclonal antibodies for treating cancer. Annals of Internal Medicine. Vol. 111. 1989. pp. 592-603.	✓
LBH		Dillman RO. Antibodies as cytotoxic therapy. Journal of Clinical Oncology. Vol. 12. 1994. pp. 1497-515.	✓
LB		Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Advances in Cancer Research. Vol. 71. 1997. pp. 343-71.	✓
LB		Dvorak HF, Nagy JA, Dvorak AJM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells. Vol. 3. 1991. pp. 77-85.	X
LBH		Engelhorn SA, Spang-Thomsen M, Brunner N, Nohr I, Vindelov LL. Disaggregation of human solid tumours by combined mechanical and enzymatic methods. Br J Cancer. Vol. 51. 1985. pp. 95-8.	X
LB		Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Research. Vol. 47. 1987. pp. 830-40.	

Examiner Signature	<i>[Signature]</i>	Date Considered	4/10/01
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/99, OMB 0051-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1419B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/727370
		Filing Date	
		First Named Inventor	DAVID YOUNG
		Group Art Unit	XXXX
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	2056.06	

JC886 U.S. PTO
09/727370
11/29/00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	TF
LK		Foon KA. Biological therapy of cancer. Breast Cancer Research & Treatment. Vol. 7. 1986. pp. 5-14.	
Lh		Franzen B, Linder S, Okuzawa K, Kato H, Auer G. Nonenzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis. Vol. 14. 1993. pp. 1045-53.	
Lgn		Harris DT, Mastrangelo MJ. Serotherapy of cancer. Seminars in Oncology. Vol. 16. 1989. pp. 180-98.	✓
Lp		Holz E, Raab R, Rietunuller G. Antibody-based immunotherapeutic strategies in colorectal cancer. Recent Results in Cancer Research. Vol. 142, 1996. pp. 381-400.	✓
Wb		Kravtsov VD, Fabian I. Automated monitoring of apoptosis in suspension cell cultures. Laboratory Investigation. Vol. 74. 1996. pp. 557-70.	✓

Examiner Signature	<i>[Signature]</i>	Date Considered	4/10/01
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.